In non-small cell lung cancer, mutations and CNVs in EGFR, KRAS and TP53 were the most common, so we focused on the prognosis of patients stratified by carrying these respective gene’s mutations only, CNV only, and co-occurring CNV and mutations using a Cox proportional hazards model that included key clinical covariates (Methods). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.